Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Biomarkers & Precision Medicine 2025

Biomarkers & Precision Medicine, now in its 20th year, is a dynamic event showcasing the latest advancements and technologies in biomarker research. This year’s program [...]

Go to Top